Serina Therapeutics said it dosed the first patient in its Phase 1b registrational clinical trial of SER-252 for advanced Parkinson’s disease. The study is designed to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy in patients whose symptoms are inadequately controlled by standard-of-care therapies. The company expects a blinded Safety Monitoring Committee review of Cohort 1 safety and tolerability data and a potential advancement to Cohort 2 in the third quarter of 2026. Serina also reported FDA alignment on a 505(b)(2) NDA pathway and said initial dosing is underway at global clinical sites, including Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.